《2006CARI指南—膜性肾病:环孢素治疗的作用》内容简介:
Idiopathic MGN is the most common form of nephrotic syndrome in **s. Althoughmany patients have a benign course or undergo spontaneous complete or partialremission, 30–40% of patients progress toward nd-stage kidney disease (ESKD)within 5–15 years (Schieppati et al 1993; Geddes et al 2000), sometimes months oryears after the onset of nephrotic syndrome and a substantial percentage of patientsnever progress to kidney failure. To avoid possibly unnecessary treatments, mostclinical studies have focused on individuals who are thought to be at greater risk forprogressive disease. The objective of this guideline is to evaluate the availableclinical evidence pertaining to the impact of cyclosporine on renal functional declinein MGN with poor prognostic features, such as heavy proteinuria (> 3 g/24 h),impaired renal function at presentation, deteriorating renal function and/orreducedresponse to therapy.
《2006CARI指南—膜性肾病:环孢素治疗的作用》内容预览:
Cattran et al (1995) randomised 51 patients with biopsy-proven idiopathicMGN and nephrotic-range proteinuria to 26 weeks of cyclosporine treatmentplus low-dose prednisone to placebo plus prednisone. Seventy five per cent ofthe treatment group vs. 22% of the control group (P < 0.001) had a partial orcomplete remission of their proteinuria by 26 weeks. Relapse occurred in 43%(N = 9) of the cyclosporine remission group and 40% (n = 2) of the placebogroup by week 52. Form this time until the end of the study at 78 weeks, thefraction of the total population in remission remained unchanged (cyclosporine39%, placebo 13%, P = 0.007)。 Renal insufficiency, defined as doubling ofbaseline creatinine, was seen in 2 patients in each group.
In a recent meta-**ysis of placebo-controlled trials of cyclosporine/prednisolone,involving 104 randomised patients, no clinically relevant beneficial effect wasobserved (Schieppati et al 2004)。 Nonetheless, partial remissions were morefrequent in cyclosporine-treated patients than in those treated with alkylating agents(partial remission RR 1.68, 95%CI: 1.06–2.65, P = 0.03).
点击下载***:《2006CARI指南—膜性肾病:环孢素治疗的作用》
肾脏亦是参与机体代谢的器官之一,尤其是在水、电解质与酸碱平衡的维持,代谢中...[详细]
造影剂肾病是碘造影剂应用过程中的重要并发症,也是医源性肾功能衰竭的重要组成...[详细]